Not to be administered by intracerebral, intrapleural or intraperitoneal routes. Must be diluted prior to IV infusion. Avoid contact w/ plasticised polyvinyl chloride (PVC) equipment, infusion lines or devices used when preparing infusion soln. Not recommended to repeat a course until patient's neutrophil count is at least 1.5 x 109
cells/L & platelet count is at least 100 x 109
cells/L. Reduce subsequent courses by 20% if severe neutropenia or severe peripheral neuropathy occur during therapy. Should be given before a platinum compd when given as combination. Premedicate before every treatment cycle w/ corticosteroids (eg, dexamethasone), antihistamines (eg, diphenhydramine or promethazine) & H2
-receptor antagonist (eg, cimetidine or ranitidine). Not to be administered in patients w/ pre-treatment neutrophil count of <1.5 x 109
cells/L or platelet count <100 x 109
cells/L. Frequently monitor blood counts during treatment; vital signs particularly during 1st hr of infusion. Monitor ECG in patients w/ serious conduction abnormalities & those who develop abnormal CV symptoms or signs during vital signs monitoring. Monitor cardiac function when used in combination w/ trastuzumab or doxorubicin. Closely monitor patients w/ a previous history of hypersensitivity to other taxanes. Continuously observe patients receiving therapy for at least 1st 30 min following start of infusion & frequently thereafter. Discontinue immediately in case of severe hypersensitivity; patient should not be rechallenged. Exclude bowel perforation in patients w/ abdominal pain. Closely monitor infusion site for possible infiltration during administration. Carefully monitor patients w/ pre-existing neuropathy. Greater incidence of neurotoxicity when used in combination w/ cisplatin in NSCLC patients. Possible CNS & other effects of alcohol. May affect ability to drive & use machines. Renal & hepatic impairment. May impair fertility in females & males of reproductive potential. Use effective contraception; males should avoid fathering a child during treatment & at least 3 mth after last dose; women of childbearing potential should avoid becoming pregnant during treatment & for at least 6 mth after last dose. May cause foetal harm when administered to a pregnant woman. Discontinue breastfeeding while mother is undergoing treatment. Paed patients. Elderly.